Anticancer effects of γ-tocotrienol are associated with a suppression in aerobic glycolysis

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 9, 2015, Pages 1352-1360

  Parajuli, Parash ^a   Tiwari, Roshan Vijay ^a   Sylvester, Paul William ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Aerobic glycolysis; Breast cancer; C Myc; Vitamin E; tocotrienol

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; GAMMA TOCOTRIENOL; GLUCOSE TRANSPORTER 1; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOENZYME; LACTATE DEHYDROGENASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRUVATE KINASE; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; GLUCOSE; MTOR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; PLASTOCHROMANOL 8; TARGET OF RAPAMYCIN KINASE;

AEROBIC GLYCOLYSIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLUCOSE INTAKE; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMANS; GLUCOSE; GLYCOLYSIS; HUMANS; LACTIC ACID; MCF-7 CELLS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; TOR SERINE-THREONINE KINASES; VITAMIN E;

EID: 84941210449     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00306     Document Type: Article

References (45)

1. De Berardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 7, 11-20 (2008).
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-1033 (2009).
3. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 4, 891-899 (2004).
4. Warburg O. On the origin of cancer cells. Science, 123, 309-314 (1956).
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 144, 646-674 (2011).
6. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov., 2, 881-898 (2012).
7. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res., 15, 6479-6483 (2009).
8. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med., 8(Suppl.), S62-S67 (2002).
9. Fan Y, Dickman KG, Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J. Biol. Chem., 285, 7324-7333 (2010).
10. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol., 27, 7381-7393 (2007).
11. McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med., 224, 292-301 (2000).
12. McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids, 35, 171-180 (2000).
13. Shah S, Gapor A, Sylvester PW. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr. Cancer, 45, 236-246 (2003).
14. Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp. Biol. Med., 229, 745-755 (2004).
15. Tiwari RV, Parajuli P, Sylvester PW. γ-Tocotrienol-induced autophagy in malignant mammary cancer cells. Exp. Biol. Med., 239, 33-44 (2014).
16. Sylvester PW, Akl MR, Malaviya A, Parajuli P, Ananthula S, Tiwari RV, Ayoub NM. Potential role of tocotrienols in the treatment and prevention of breast cancer. Biofactors, 40, 49-58 (2014).
17. Samant GV, Sylvester PW. γ-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif., 39, 563-574 (2006).
18. Parajuli P, Tiwari RV, Sylvester PW. Antiproliferative effects of γ-tocotrienol are associated with a suppression in c-Myc expression in mammary tumor cells. Cell Prolif., 48, 421-435 (2015).
19. Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W. γ-Tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. Br. J. Nutr., 99, 1247-1254 (2008).
20. Xu W, Du M, Zhao Y, Wang Q, Sun W, Chen B. γ-Tocotrienol inhibits cell viability through suppression of β-catenin/Tcf signaling in human colon carcinoma HT-29 cells. J. Nutr. Biochem., 23, 800-807 (2012).
21. Ananthula S, Parajuli P, Behery FA, Alayoubi AY, Nazzal S, El Sayed K, Sylvester PW. γ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl 2-induced hypoxia. Biomed Res. International., 2014, 1-13 (2014).
22. Ananthula S, Parajuli P, Behery FA, Alayoubi AY, El Sayed KA, Nazzal S, Sylvester PW. EL Sayed KA, Nazzal S, Sylvester PW. Oxazine derivatives of γ- and ä-tocotrienol display enhanced anticancer activity in vivo. Anticancer Res., 34, 2715-2726 (2014).
23. Malaviya A, Parajuli P, Sylvester PW. Anticancer effects of combined γ-tocotrienol and PPARγ antagonist treatment are associated with a suppression in adipogenic factor expression. J. Pharm. Nutr. Sci., 4, 43-56 (2014).
24. Anderson LW, Danielson KG, Hosick HL. Epithelial cell line and subline established from premalignant mouse mammary tissue. In Vitro, 15, 841-843 (1979).
25. Anderson LW, Danielson KG, Hosick HL. Metastatic potential of hyperplastic alveolar nodule derived mouse mammary tumor cells following intravenous inoculation. Eur. J. Cancer Clin. Oncol., 17, 1001-1008 (1981).
26. Danielson KG, Anderson LW, Hosick HL. Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res., 40, 1812-1819 (1980).
27. Wali VB, Bachawal SV, Sylvester PW. Combined treatment of γ-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp. Biol. Med., 234, 639-650 (2009).
28. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. Optimizing the production of suspension cells using the G-Rex "M" series. Mol. Ther. Methods Clin. Dev., 1, 14015 (2014).
29. Shirode AB, Sylvester PW. Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment. J. Bioanal. Biomed., 3, 1-7 (2011).
30. Wali VB, Bachawal SV, Sylvester PW. Endoplasmic reticulum stress mediates γ-tocotrienol-induced apoptosis in mammary tumor cells. Apoptosis, 14, 1366-1377 (2009).
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology, 24, 145-149 (1992).
32. Cheng G, Zielonka J, McAllister DM, Mackinnon AC Jr, Joseph J, Dwinell MB, Kalyanaraman B. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer, 13, 285 (2013).
33. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene, 25, 4683-4696 (2006).
34. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB, Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell, 24, 213-228 (2013).
35. Lincet H, Icard P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene, 34, 3751-3759 (2015).
36. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol., 43, 969-980 (2011).
37. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452, 230-233 (2008).
38. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 463, 364-368 (2010).
39. Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol., 2013, 242513 (2013).
40. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Al Dape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol., 14, 1295-1304 (2012).
41. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U. S. A., 108, 4129-4134 (2011).
42. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol. Cancer, 12, 152 (2013).
43. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, Yang DP, Mo SL, Guan XY, Chen JP. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res. Treat., 131, 791-800 (2012).
44. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest., 123, 3685-3692 (2013).
45. Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res., 74, 908-920 (2014).